Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615
administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with
high cholesterol whose LDL-cholesterol is >/=80 mg/dL on background treatment with a statin.